CP and Immunodeficiency: Successful treatment with a combination of remdesivir and CP after failure of single agent remdesivir (10, 13), CP or standard IV Ig (25) in the setting of protracted disease has been reported both in post-rituximab and in primary B cell immune deficiencies.